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Background: Inflammatory Bowel Disease (IBD), which includes both Crohn’s disease (CD) and ulcerative colitis
(UC), is caused by a complex interplay involving genetic predisposition, environmental factors and an infectious
agent. Mycobacterium avium subsp. paratuberculosis (MAP) is a promising pathogen candidate since it produces a
chronic intestinal inflammatory disease in ruminants that resembles CD in humans. MAP is a ubiquitous
microorganism, although its presence in the food chain, especially in milk from infected animals, is what made us
think that there could be an association between lactase persistence (LP) and IBD. The LCT mutation has brought
adaptation to dairy farming which in turn would have increased exposure of the population to infection by MAP.
NOD2 gene mutations are highly associated to CD.
Methods: In our study, CD and UC patients and controls from the North of Spain were genotyped for the lactase
gene (LCT) and for three NOD-2 variants, R702W, G908R and Cins1007fs. MAP PCR was carried out in order to assess
MAP infection status and these results were correlated with LCT and NOD2 genotypes.
Results: As for LP, no association was found with IBD, although UC patients were less likely to present the T/T−13910
variant compared to controls, showing a higher C-allele frequency and a tendency to lactase non-persistence (LNP).
NOD2 mutations were associated to CD being the per-allele risk higher for the Cins1007fs variant. MAP infection
was more extended among the healthy controls (45.2%) compared to CD patients (21.38%) and UC patients
(19.04%) and this was attributed to therapy. The Asturian CD cohort presented higher levels of MAP prevalence
(38.6%) compared to the Basque CD cohort (15.5%), differences also attributed to therapy. No interaction was found
between MAP infection and LCT or NOD2 status.
Conclusions: We conclude that LP is not significantly associated with IBD, but that MAP infection and NOD2 do
show not mutually interacting associations with IBD.
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Inflammatory bowel disease (IBD) is a pathological enter-
itis characterized by chronic regional inflammatory infil-
trate of the intestinal wall and associated lymph nodes
that comprises Crohn’s disease (CD) and ulcerative colitis
(UC). Etiology of IBD remains unclear, although inflam-
mation can be a result of inappropiate chronic activation
of the innate and adaptive mucosal immune systems in
individuals with genetic modifications [1]. Exposure to
pathogens seems to be a potential cofactor for disease de-
velopment [2] meaning that the disease could be induced
by an infectious agent in genetically susceptible indivi-
duals. Mycobacterium avium subsp. paratuberculosis
(MAP) is a probable pathogen candidate for at least one
subtype of IBD, CD, since it is responsible for a disease in
ruminants of similar clinical and histological conditions
named Johne’s disease (JD) or paratuberculosis [3-5]. The
connection between both intestinal inflammatory bowel
diseases, human and ruminant, was first described in the
early 1900s [6,7].
Although the possible link between MAP and CD
remains controversial, improvements in isolation [8,9] and
genetic techniques [10-14] are providing evidence that
MAP might play a causative role in the development of
CD along with genetic [15] and immunological factors
[16]. Mutations in the NOD2 locus are highly associated
with CD in Europeans [17] and a recent genome-wide
study from China [18,19] has shown that a high propor-
tion of leprosy patients have many of the same genetic
mutations found in patients with CD including NOD2/
CARD15 mutation. All these findings lend support to the
mycobacterial etiological hypothesis in CD.
Lactase deficiency has been commonly found in adults
with IBD, mainly in CD patients. In fact, lactase non-
persistence (LNP) was thought to be a predisposing co-
factor that could activate the disease. Some studies have
shown that the prevalence of LNP is greater in IBD
patients compared to controls [20-22] and more com-
mon in patients with CD (40-46%) when compared to
UC (13-16%) [20,22].
Previously [23], we raised the hypotheses that a correl-
ation between LNP and CD incidence could support the
idea that MAP is the causative agent of CD. Lactase per-
sistence (LP) dominant mutation could have been origi-
nated as a consequence of adaptation to dairy-farming
and exposing humans to MAP through milk consump-
tion and overall close contact with infected cattle. In our
observational epidemiological study higher CD incidence
correlated with lower LNP frequency, this is higher LP
frequency. Similar conclusions were drafted by a recent
meta-analysis that studied the impact of lactose on LP
and IBD, among other diseases [24].
When assessing previous studies we find that the rela-
tion between CD and LNP is also questionable [25-27].Buning et al. [28] genotyped for the lactase gene (LCT)
which encodes for the lactose phlorizin hydrolase (LPH)
that splits lactose in the small intestine and failed to find
an association between the C/C−13910 and G/G−22018 geno-
types, accepted markers for LNP, with susceptibility to CD
and UC. However, Nolan et al [29] showed an association
between LP and the risk of CD in New Zealand.
Since, both UC and CD are thought to be multifactor-
ial disorders where polygenic dysfunction could be the
ground for inflammatory changes triggered by MAP.
The aim of the present work was to study the possible
interplay of genetic susceptibility for LNP (LCT status)
and CD (NOD2 status) and the presence of MAP among
IBD patients and controls from the North of Spain that
would support an etiological role of MAP.
Results
Complete data for MAP DNA presence in blood and both
LCT and NOD-2 genotyping was accomplished for 278
subjects with IBD (173 with CD and 105 with UC) and
188 healthy controls. Demographic data, etiology of dis-
ease and therapy of these 466 individuals is shown on
Table 1. Equal number of women and men were recruited
and no significant differences in gender were found among
groups. UC individuals were older than CD patients (p
< 0.0001) and healthy controls (p= 0.002), probably being
due to subject enrollment.
The LCT genotypes for all subjects were analyzed and
our results revealed a frequency of 21.2% for the LNP C/C
−13910 genotype. LCT genotype distribution followed the
Hardy-Weinberg principle. The frequencies of C/T−13910
alleles and genotypes stratified as a function of IBD type are
presented in Table 2. No significant differences were
detected on the percentage of C/C−13910 variants among
UC and CD patients (25.7 and 21.4%, respectively) and
healthy controls (18.6%). However, remarkably lower pres-
ence of the T/T−13910 variant was observed among UC
patients (22.9%) compared to controls (38.3%) (p=0.0075).
The frequency of the T/T−13910 variant tended to be higher
when UC patients and CD patients were compared
(p=0.1005). UC patients present a higher C allele frequency
(51.4%) compared to healthy controls (40.2%) (p=0.0091)
and CD patients (45.5%) (p=0.1775).
NOD2 allele and genotype frequencies are summar-
ized in Table 3. NOD2 mutation prevalence among CD,
UC and HC were 23.69%, 8.51% and 12.76%, respect-
ively. Homocygotes for R702W were only found in IBD
patients and 1007 fs mutation rate was significantly
higher in CD patients compared to UC (p = 0.021) and
controls (p = 0.0135). Double mutants were only present
in IBD patients, 9 (5,20%) in CD and 1 (0,95%) in UC
patients. 1007 fs mutation was associated to upper di-
gestive tract (OR, 8.37; 95% 1.26-55.45, P = 0.01) and in
less extent to ileum (OR, 2.74; 95% 0.81-9.32, P = 0.095)
Table 1 Demographic information and etiology of
Inflammatory Bowel Disease patients and controls
CD UC HC
(n= 173) (n = 105) (n = 188)
Gender (%female) 50,86 53,33 53,15
Age (yr)
Mean 38,4+/−12,2 44,9+/−12,9 40,0+/−12,94
Range 16–77 21–69 19–61
ND 16,5 % 8 %
Drugs (%)
Azathioprine 43,35 15,20 -
Budenoside 3,47 4,80 -
Infliximab 15,60 2,90 -
Mesasalazine 57,23 63,80 -
Metronidazol 4,62 2,90 -
Prednisolone 8,67 11,40 -
Disease Location (%)
Rectum (E1) - 41,90 -
Left colon (E2) - 17,10 -
Colon (E3, L2) 12,70 31,40 -
Ileum (L1) 42,2 - -
Ileocolon (L3) 30,60 - -
Upper digestive tract (L4) 2,90 - -
ND 11,60 9,50 -
Active Disease (%) 16,18 14,28 -
CD: Crohn’s Disease, UC: Ulcerative colitis, HC: Healthy Controls, ND: Not
determined.
Table 3 The distribution of NOD2 genotypes in patients
with inflammatory bowel disease (IBD), Crohn’s disease
(CD), ulcerative colitis (UC) and in controls (HC) [n (%)]
NOD2 genotype frequency n (%)
Group WT/WT Heterocygotes Homocygotes
IBD (n=278)
R702W 241 (86.7) 34 (12.2) 3 (1.1)
G908R 273 (98.2) 5 (1.8) 0 (0.0)
1007 fs 263 (94.6) 15 (5.4) 0 (0.0)
CD (n=173)
R702W 145 (83.8) 26 (15.0) 2 (1.2)
G908R 168 (97.1) 5 (2.9) 0 (0.0)
1007 fs 158 (91.3) 15 (8.7)* 0 (0.0)
UC (n=105)
R702W 96 (91.4) 8 (7.6) 1 (1.0)
G908R 105 (100.0) 0 (0.0) 0 (0.0)
1007 fs 105 (100.0) 0 (0.0) 0 (0.0)
HC (n=188)
R702W 171 (91.0) 17 (9.0) 0 (0.0)
G908R 186 (98.9) 2 (1.1) 0 (0.0)
1007 fs 183 (97.3) 5 (2.7) 0 (0.0)
WT: Wild-type
* 1007 fs allele frequency, CD versus UC (p = 0.021) and CD versus controls
(p = 0.0135).
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MAP presence detected by PCR was more frequent in
healthy controls (45.2%) than in CD or UC patientsTable 2 The distribution of LP/LNP genotypes and allele
frequencies in patients with inflammatory bowel disease
(IBD), Crohn’s disease (CD) ulcerative colitis (UC) and in
controls (HC) [n (%)]
Allele
Genotype Frequency %
Group CC-139101* CT-139102 TT-1319102 C T
IBD (n=278) 64 (23.0) 138 (49.6) 76 (24.4)a 47.8 52.2
CD (n=173) 37 (21.4) 84 (48.6) 52 (30) 45.5 54.5
UC (n=105) 27 (25.7) 54 (51.4) 24 (22.9) b 51.4 48.6
HC (n=188) 35 (18.6) 81 (43.1) 72 (38.3) 40.2 59.8
1Lactase non-persistent genotype (LNP); 2Lactase persistent genotype (LP) *No
significant differences were detected comparing LNP and LP genotypes
between UC patients and CD patients (P= 0.409), CD patients and controls
(P= 0.506) or IBD with controls (P= 0.255). Nearly significant differences
comparing UC patients and controls (P= 0.154). Significant differences were
detected when comparing TT genotype, aIBD and controls (P= 0.013) and bUC
patients compared to controls (P= 0.0075). Nearly significant difference when
comparing CD patients and controls (P= 0.1005).(21.38 and 19.04%, respectively). We next compared
whether the frequency of MAP detection differed de-
pending on the particular disease characteristics of
patients. The affected area of the digestive tract did not
correlate with MAP PCR result. No interaction was
found when disease activity and MAP PCR result were
compared in the CD group (OR, 0.768; 95% 0.27-2.18
p = 0.619). However, a suggestion of interaction was
observed in the UC group (OR, 2.5; 95% 0.75-8.4
p = 0.128), meaning that MAP was detected more fre-
quently in patients with active disease at sampling
period in this cohort. Because therapy consisted in a
combination of drugs in most cases, these could not be
analyzed individually. No association was found when
MAP presence was compared to drug combinations.
Only when azathioprine was administered along with
other drugs for CD therapy an interaction was found
with MAP DNA in blood (OR, 2.29; 95% 1.09-4.82,
P = 0.026), meaning that azathioprine combined with
other drugs would not be effective in achieving MAP
clearance.
When comparing MAP status with analyzed SNPs
for LCT and NOD2 no association was found. More
MAP infected individuals among the T/T−13910 genotype
subjects (33.78%) were detected as compared to the
C/C−13910 (28.28%) or C/T−13910 carriers (29.22%), although
differences were not significant. Distribution of MAP
Table 5 Frequencies of LCT genotypes, NOD2 mutant
carriers and mutations, and MAP PCR in the subgroups of
CD patients [n (%)]
Asturias Basque country P
(n = 44) (n = 129)
LCT genotype
CC 8 (18.2) 29 (22.5) 0.5490
CT 19 (43.2) 65 (50.4) 0.4104
TT 17 (38.6) 35 (27.1) 0.1525
NOD2 mutants 8 (18.2) 33 (25.6) 0.3204
R702W 6 (13.6) 20 (15.5) 0.7610
G908R 0 (0.0) 5 (3.9) 0.1855
1007 fs 2 (4.5) 13 (10.1) 0.2561
MAP PCR positive 17 (38.6) 20 (15.5) 0.0015
Table 6 Multivariate logistic regression analysis of risk
factors for subjects with inflammatory bowel disease
(IBD), Crohn’s disease (CD) or Ulcerative Colitis (UC)
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sented on Table 4.
Subgroup analyses considering the Basque and Astur-
ian CD patient cohort separately revealed no significant
differences except for MAP infection as shown on
Table 5. In this case, 38.6% of the Asturian CD patients
were MAP PCR positive compared to 15.5% of the
Basque CD subjects (p = 0.0015). Since differences in
drug therapy could be a playing a role, we next analyzed
the number of patients taking each drug and their MAP
PCR result in both subgroups. Azathioprine showed to
be less effective in Asturian patients (p< 0.0001),
whereas effectiveness of Infliximab and prednisone was
not significantly different among CD patients in both
regions (p = 0.0738 for both).
The multivariate logistic regression analysis for IBD,
CD and UC is summarized on Table 6. Testing for sig-
nificant interactions between MAP infection, C/T−13910
genotype variants and presence of NOD-2 mutations for
each group was performed. CD patients were less likely
to be infected with MAP compared to controls (OR=
0.33, 95% CI, 0.21-0.53) and the likelihood of CD
patients of being C/C−13910 or C/T−13910 carriers was
similar to that of controls (OR= 1.44, 95% CI, 0.93-2.24)
although a slight tendency was observed. For UC the
trends regarding MAP infection were almost the same, i.
e. less likely to be infected by MAP as compared to con-
trols (OR= 0.29 95% CI, 0.16-0.50). However, among UC
patients, it was much more likely to find a C allele car-
rier, i.e. a C/C−13910 or C/T−13910 genotype (OR= 2.16,
95% CI. 1.25-3.71). The model shows that MAP infec-
tion detection by blood PCR is less common in IBD
patients compared to controls, not being predictive of
disease. T/T−13910 genotype is less common in UC
patients. It was more likely to find NOD-2 mutation car-
riers among CD patients.Table 4 NOD2 and LCT mutation distribution in MAP
infected and non-infected individuals among Crohn’s





CD (n = 173) UC (n = 105) HC (n= 188)
MAP + MAP - MAP + MAP - MAP + MAP -
NOD2
0 29 (16.76) 103 (59.54) 19 (18.10) 77 (40.96) 77 (40.96) 87 (46.28)
1 7 (4.05) 26 (15.03) 1 (0.95) 7 (6.67) 8 (4.26) 16 (8.51)
2 1 (0.58) 7 (4.05) 0 (0.00) 1 (0.95) 0 (0.0) 0 (0.00)
LCT
0 27 (15.61) 109 (63.01) 14 (13.33) 64 (60.95) 73 (38.83) 80 (42.55)
1 10 (5.78) 27 (15.61) 6 (5.71) 21 (20.00) 12 (6.38) 23 (12.23)
No significant differences were detected among groups except for CD versus
HC NOD2 0 and CD versus HC LCT 0 (p< 0.0001).Discussion
IBD and particularly CD are now thought to be the out-
come of a complex synergism produced by predisposing
genetic and environmental factors along with an infec-
tious agent or shift in normal bacterial flora. The simi-
larities that have been outlined between CD in humans
and JD in both domestic and wildlife animals force us to
look into mycobacteria, with a special focus on MAP.
The main goal of this study was to indirectly demon-
strate the mycobacterial role in CD by finding a correl-
ation between LP and CD. This theory can be explained
as a result of substantial milk consumption and the
increased dairy ruminant farming associated to the in-
take of viable MAP both from milk and meat, and from
environmental contaminated food in the LP adaptedversus those of healthy controls
Odds ratio (95% CI) P
CD (n=173)
C allele carrier in LCT 1.44 (0.93-2.24) 0.1
MAP (PCR positive vs PCR negative) 0.33 (0.21-0.53) <0.0001
NOD-2 mutant 2.05 (1.18-3.58) 0.011
UC (n=105)
C allele carrier in LCT 2.16 (1.25-3.71) 0.005
MAP (PCR positive vs PCR negative) 0.29 (0.16-0.50) <0.0001
NOD-2 mutant 0.67 (0.30-1.51) 0.338
IBD (n =278)
C allele carrier in LCT 1.65 (1.11-2.45) 0.013
MAP (PCR positive vs PCR negative) 0.31 (0.21-0.47) <0.0001
NOD-2 mutant 1.74 (1.00-3.01) 0.046
In this analysis C allele carrier and MAP presence were treated as categorical
values. Significance was considered when P< 0.05.
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accepted susceptibility marker for CD, NOD2 and MAP
status was sought. Our initial hypotheses have not been
confirmed since we failed to find a significant association
of LP with IBD or MAP infection, meaning that such
correlation does not exist, at least in our study popula-
tion. However, we can contribute with other interesting
observations that will be further discussed.
We found that the frequency for LNP (C/C−13910 var-
iants) in the North of Spain was 21.2%. This result
agrees with previous studies for other European popula-
tions [30-32] where the prevalence of LNP in the general
population was 15-25%. However studies conducted with
subjects from other parts of Spain render LNP preva-
lences of 40.1% [33], 39.6% [34] and 34.6% [35]. The
Basque Country and Asturias are historically milk pro-
ducing regions. The climate in these areas presents less
insolation compared to other parts of Spain and milk
consumption might be an advantage for calcium absorp-
tion [32]. In this sense, higher T allele frequencies could
be explained as the result of a certain biological advan-
tage conferred by higher levels of milk consumption in
adult life as a result of animal domestication and cultur-
ally transmitted practice of dairying [36].
Although other studies have assessed other SNPs [28],
in our case, we only looked for the C/T−13910 variants
since SNP G/A−22018 is thought to be in a linkage dis-
equilibrium with the SNP C/T−13910 [27].
When LCT genotypes were analyzed among groups, a
significant lower frequency of the T/T−13910 genotype was
found in UC patients. We are not sure about the meaning
of this finding. In any case, if the C!T switch can be
considered an adaptation, and T is dominant, an individ-
ual with T/T−13910 genotype would guarantee the transfer
of adaptation to its progeny. Less T/T−13910 genotype indi-
viduals among UC patients would finally result in an in-
crease in C/C−13910 and C/T−13910 progeny leading to a
boost of LNP among UC patients. Some authors have sug-
gested that UC have ethnically dependent increased rates
of lactose intolerance [20-22], while other studies report
that symptoms of milk protein allergy resemble UC conse-
quently representing a subtype of the disease [37,38]. Our
results show a tendency that supports both ideas.
Recently, Nolan et al [29] have reported that the T allele
encoding LP was associated with an increased risk of CD
in New Zealand. This discovery is in accordance with our
initial hypothesis and with a previous study run by our
group [39]. In that case a smaller population was studied
and T allele frequency was higher in CD patients (61.9%)
than controls (47.1%). Other studies have failed to detect
significant differences when comparing the LCT genotype
variants between CD or UC patients and controls [28].
Our present study shows similar T allele frequencies
among cohorts and only marginally significant differences(p = 0.065) have been observed between the UC and HC
groups. The discrepancy in results among studies could be
due to sample size or to real differences between popula-
tions, either genetic or environmental, or both. In any
case, our findings could lead to a hypothetical polymorph-
ism that would be responsible for the different pathology
of CD and UC, although we cannot discard that the asso-
ciation is simply accidental.
The NOD2 (nucleotide-binding oligomerization do-
main containing 2) protein is a receptor that interacts
with muramyl dipeptide participating in the recognition
of bacterial peptidoglycans in general [40]. Mycobacteria
can therefore be recognized by this receptor [41] and a
lost of function in NOD2 may in consequence lead to a
decreased ability in keeping mycobacterial infections
under control. We have assessed three independent
mutations within the NOD2 gene [42] that are accepted
to be associated to CD in Europeans, in order to assess
NOD2 status among two populations in the North of
Spain and also to relate it to MAP detection, since we
hypothesize that subjects with a defective NOD2 will be
infected with MAP.
NOD2 prevalence in CD patients was 23.69%, similar to
that observed in other studies carried out in Europeans
[43,44]. A higher number of individuals were found to
present mutations in the CD group and double mutants
were only detected in the IBD group, as expected. However,
if we look at the different SNPs separately, only 1007 fs mu-
tation carriers were significantly more abundant in the CD
pool as compared to the UC and HC groups. Results pre-
sented in a report that summarizes geographic differences
in the Spanish population concerning NOD2 support these
findings [45]. In this work diversity in the SNP distribution
for the NOD2 gene in different Spanish regions is
described. The most remarkable result is that in the Gal-
ician and Asturian samples, NOD2 mutations do not al-
ways correlate with CD, since significant differences are not
recognized when compared to the controls. This was the
case for SNPs 8 (R702W) and 12 (G908R). This can be par-
tially expected since SNP13 (1007 fs) is a loss of function
mutation that should definitely correlate better with disease.
In our present study, samples from CD patients from As-
turias have been included along with samples from patients
and controls from the Basque Country. The similarity be-
tween Asturias, Galicia and the Basque Country is that all
regions are located in the Northern most part of Spain.
These results may mean that the entire population in the
North of Spain carries higher NOD2 mutation frequencies
but not all of the individuals have developed or have been
diagnosed CD. In this case, environmental factors should
be considered.
Although NOD2 genetic variation has been related to
ileal CD [43,46], we did not find clear associations between
mutations and disease type in CD or UC patients, except
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patients with upper digestive tract and ileal affections.
A great effort has been made to demonstrate the connec-
tion between MAP infection and IBD. MAP DNA detec-
tion has been found to be highly predictive of CD in some
studies [10,47]. This was not so in previous studies carried
out by our group, where we found that DNA from MAP
was detected in a higher number of healthy individuals
compared to IBD patients [12,13]. Once again, results pre-
sented in this report show that MAP infection is more
extended among healthy individuals compared to CD or
UC patients in the North of Spain. Frequent detection of
MAP DNA in blood of humans may be due to the wide
distribution of MAP in the environment and its presence in
the food chain. MAP‘s recent isolation from meat products
[48-50] and its presence in milk [51], makes these part of a
transmission route that goes direct to human beings if these
are not cooked appropriately [52]. The observation of
higher frequencies of MAP in healthy controls than in
patients is controversial, but it is compatible with a slow in-
fection model of pathogenesis where healthy carriers that
do not develop the disease are a larger proportion of the
population than that showing clinical signs. Lower rates
among clinical cases could be explained as the result of a
reduction of bacterial burden by the antibiotic effect of
standard IBD therapy [12]. Another hypothesis that could
explain the IS900 PCR rates would be the presence of “pro-
tective strains” in Northern Spain. In this case, the entire
population would be exposed to these strains. The group of
subjects that mounts an appropriate immune response
would benefit from infection, whereas genetically suscep-
tible individuals with immune disregulation and/or dysbio-
sis would not be immunized correctly and would develop
disease after infection with a non-protective strain. These
diseased subjects would be administered therapy that would
partially eliminate MAP and for this reason less MAP DNA
would be detected among IBD patients. This hypothesis is
less likely because it is more complex since it requires, in
addition to the treatment effect, the existence a new type of
MAP, the “protective” strains, that had never before been
postulated. It is also possible that the IS900 PCR on periph-
eral blood might not be as efficient in detecting viable MAP
(in patients) as in detecting non-viable MAP (in individuals
controlling the infection). The difficulty with most of these
explanations is that they are not specific of the populations
we have studied and the control/patient ratio inversion
should have been detected in other studies.
When subgroups were analyzed separately there were
more MAP PCR positive CD patients in Asturias than in
the Basque Country. Accordingly with the first hypoth-
esis, we think that different response to therapies can be
influencing this result.
The rationale for the present study was that there would
be a correlation of MAP presence, LNP and NOD2 mutantcarriage. This is the first work that intends to find this link.
Other research groups have also failed to find interaction
between NOD2 status and MAP presence in IBD [53]. In
that case, the method used for addressing MAP infection
was serological and we thought that MAP PCR could be
more sensitive.Conclusions
Although previous studies have suggested an association
between LNP and IBD at a population level, our study
failed to find an association between the C/C−13910 geno-
type and IBD at an individual level. From these results
we conclude that there is not a direct correlation be-
tween IBD and LNP although the C allele is more fre-
quent in UC patients and this could be translated as a
tendency to LNP among these patients. MAP infection
is widely spread among the general population although
it is not associated to LNP or to NOD2 status and it is
more common in healthy individuals not under conven-
tional IBD therapy. As for NOD2, this is the first study
to our knowledge where NOD2 status has been assessed
in a Basque population and as expected more mutant
carriers were detected among CD patients in the whole.
Future studies should address a larger sample of
patients and controls from different geographical regions
within the same country and measure possible environ-
mental aspects of each region as well as culture and
dietary habits. Our results do not support a conventional
explanation for a mycobacterial etiology of IBD, even
taking into account the genetic markers included in this
study. However, these results seem to confirm an unex-
pected association that needs to be clarified in future
studies. In this sense, the current opinion that IBD has a
genetic origin triggered by an external agent still is the
most plausible. Demonstration that this agent is or is
not MAP would require the improvement of detection
tools, the selection of the correct specimens and the
monitoring of the presence of the microorganism
through a period of time, as well as looking into genetic
factors.Methods
Study population
Using a case–control design, IBD patients (n= 278) were
recruited from three hospitals from the Basque Country:
The Quirón Donostia Clinic in Gipuzkoa, the Hospital
de Txagorritxu in Araba , and the Hospital de Galdakao
in Bizkaia, and one hospital from the Principado de As-
turias, Hospital Universitario Central de Asturias in Ovi-
edo. Non-IBD patients designated as healthy controls
(n= 188) were recruited from the Basque Country Blood
Bank. A signed informed consent was obtained from all
patients and controls who participated in the study.
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Whole blood samples were obtained from each subject.
All blood samples were coded to conceal the patient's
identity and diagnosis to laboratory workers. All samples
were processed within 4 hours after extraction in a class
II bio-safety cabinet.
Genomic DNA was extracted from buffy coat cells as
described previously [12] and it was used both for MAP
IS900 nested PCR and genotyping. Briefly, one volume
blood was incubated with one volume 155 mM ammo-
nium chloride for 20 minutes to lyse the red blood cells.
The tube was centrifuged (10 min 200× g), the cell pellet
washed twice with PBS and recentrifuged (10 min
200× g). DNA was extracted and purified (QIAamp DNA
Blood Mini Kit (QIAGEN GmbH, Hilden, Germany) and
stored at −20°C until further use.
Genotyping
LCT
Genotyping of the C/T−13910 (rs4988235) SNP was carried
out by PCR–RFLP as described previously [54]. Briefly, gen-
omic DNA went through PCR-RFLP using primers LCT-
mod (5’-GCA ATA CAG ATA AGATAATGG AG-3’) and
LCT-rev (5’-CCT CGT TAA TAC CCA CTG AC-3’). The
PCR was carried out for 30 cycles of 94°C for 10 s, 52°C for
10 s, and 72°C for 10s. The amplification product (137 bp)
was digested with NlaIV (GGN^NCC recognition site) 1U/
reaction for 3 h at 37°C. When C was present in the poly-
morphic position, NlaIV digestion generated two fragments
(22 and 115 bp). Digestion products were separated by 3%
agarose gels electrophoresis and visualized after staining
with gel red (Biotium).
NOD2
Genotyping of the CARD15/NOD2 gene was carried out
by PCR–RFLP as described by Heliö [55]. Briefly, each
NOD2 variant was assayed using initial amplification of
the DNA sample by polymerase chain reaction (PCR)
and subsequent analysis of the PCR products by restric-
tion enzyme cleavage and gel electrophoresis on 12%
polyacrylamide (R702W) or 3% agarose (G908R and
1007 fs).
Detection of the R702W (Arg702Trp:SNP8, rs2066844)
mutation was done with forward primer, 5′-AGATCA
CAGCAGCCTTCCTG-3′ and reverse primer, 5′- CACG
CTCTTGGCCTCACC-3′. The PCR product (185 bp in
size) was digested at 37°C for 16 hours with 2 U of MspI,
resulting in the following fragments: 20, 35, 54, and 76 bp
in R702R homozygotes; 20, 35, 54, 76, and 130 bp in
R702W heterozygotes; and 20, 35, and 130 bp in W702W
homozygotes.
For assay of the G908R (Gly908Arg: SNP12, rs2066845) muta-
tion, 5′- CTCTTTTGGCCTTTTCAGATTCTG-3′ was used
as the forward primer and 5′-CAGCTCCTCCCTCTTCACCT-3′ as the reverse primer. The PCR product size from these pri-
mers is 163 bp. After digestion for 16 hours at 37°C with 2 U of
Hha I, the following fragments were obtained: 163 bp in G908G
homozygotes; 27, 136, and 163 in G908R heterozygotes; and 27
and 136 bp in R908R homozygotes.
In order to detect the 1007 fs (Leu1007fsinsC: SNP13,
3020insC) mutation, PCR was carried out using the forward
primer 5′- GGCAGAAGCCCTCCTGCAGGGCC-3′ and
the reverse primer 5′- CCTCAAAATTCTGCCATTCC-3′
resulting in an amplified fragment of 151 bp in size. After
digestion for 16 hours at 37°C with 2 U of ApaI, the follow-
ing panel was obtained (leucine represents the codon 1007
in the wild-type allele): 151 bp for Leu1007Leu homozy-
gotes; 20, 131, and 151 bp in Leu1007Pro heterozygotes;
and 20 and 131 bp in Pro1007Pro homozygotes.
Detection of Mycobacterium avium subsp. paratuberculosis
IS900 nested PCR was performed as described previ-
ously [12]. Briefly, first round PCR was performed with
genomic DNA and primers P90 (5’-GTT CGG GGC
CGT CGC TTA GG-3’) and P91 (5’-GAG GTC GAT
CGC CCA CGT GA-3’) generating a 398 PCR fragment.
In the second round, PCR products from the first round
were used as DNA template with primers AV1 (5’-ATG
TGG TTG CTG TGT TGG ATG G-3’) and AV2
(5’-CCGCCGCAATCAACTCCAG-3’). The final amplifi-
cation product was 298 bp long. MAP DNA (ATCC
19698) was used as positive control and run along with
the samples.
Amplicon verification
The identity of the amplicons in all cases was confirmed
on samples from two positive healthy controls and 2 IBD
patients. For MAP verification the same PCR described
for detection ending in a 298 bp amplicon was performed.
To confirm the C/T−13910 SNP genotyping, primers
LACT1-for (5’-GCA TAA AGA CGT AAG TT-3’) and
LACT1-rev 5’-ATA TGT TTA CGT TGG ATT CC-3’)
[54] were used to generate the amplicon (155 bp). Finally,
for NOD2 confirmation the same PCRs described in the
genotyping was performed for all three SNPs.
In all cases, bands were excised, extracted and purified
(GFX PCR DNA and Gel Band purification kit. Amer-
sham Biosciences, Buckinghamshire, UK). Electrophor-
esis was performed using an ABI 3130 Genetic analyzer
(Applied Biosystems) and base calling was done by Se-
quencing Analysis 5.2 Software (Applied Biosystems).
The obtained sequences were submitted to alignment
analyses.
Statistical analysis
Frequency differences and Hardy-Weinberg equilibrium
for the distribution of genotypes among the different
groups were tested with chi-squared test. Multiple
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healthy controls, UC versus healthy controls and IBD
(CD and UC combined) versus healthy controls in order
to assess the relationship between genotypes and risk of
disease. Adjusted values were estimated with 95% confi-
dence limits (CI). P values below 0.05 were considered
significant. All statistical analyses were performed using
the SAS statiscal package (SAS Insititute Inc., Cary, NC,
USA).
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